Heart

Cannabis use linked to increased risk of major adverse cardiovascular events

June 25, 2025

Study details: This systematic review and meta-analysis included 24 pharmacoepidemiological studies (17 cross-sectional, 6 cohort, 1 case-control) published between 2016 and 2023, evaluating the association between cannabis or cannabinoid use and major adverse cardiovascular events (MACEs), including cardiovascular death, non-fatal acute coronary syndrome (ACS), and non-fatal stroke. Study quality was assessed using the ROBINS-E tool, and adjusted effect estimates were pooled using a random effects model.

Results: Cannabis use was associated with a statistically significant increased risk of ACS (risk ratio [RR], 1.29; 95% confidence interval [CI], 1.05–1.59), stroke (RR, 1.20; 95% CI, 1.13–1.26), and cardiovascular death (RR, 2.10; 95% CI, 1.29–3.42). No significant association was found for a composite outcome of ACS and stroke in the two studies that reported this. Results from cohort studies were consistent with the primary analysis (RR, 1.32; 95% CI 1.01–1.73).

Clinical impact: A positive association between cannabis use and MACE was observed, supporting the need for routine assessment of cannabis use in patients presenting with cardiovascular disorders. Clinicians should be aware of these risks and consider cannabis exposure in cardiovascular risk stratification and patient counseling.

Source:

Storck W, et al. (2025, June 17). Heart. Cardiovascular risk associated with the use of cannabis and cannabinoids: a systematic review and meta-analysis. https://pubmed.ncbi.nlm.nih.gov/40527600/